Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 6, 2013, Pages

  Belov, Artur A ^a   Mohammadi, Moosa ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ALTERNATIVE RNA SPLICING; ARTICLE; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; GENETICS; HUMAN; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; DIMERIZATION; FIBROBLAST GROWTH FACTORS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION; PHOSPHORYLATION; PROTEIN CONFORMATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84878942800     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a015958     Document Type: Article

References (179)

1. Acland P, Dixon M, Peters G, Dickson C. 1990. Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon. Nature 343: 662-665.
2. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. 1998. Apert syndrome mutations in fibroblast growth factor receptor2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7: 1475-1483.
3. Asada M, Shinomiya M, Suzuki M, Honda E, Sugimoto R, Ikekita M, Imamura T. 2009. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim Biophys Acta 1790: 40-48.
4. Bae JH, Boggon TJ, Tome F, Mandiyan V, Lax I, Schles-singer J. 2010. Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proc Natl Acad Sci 107: 2866-2871.
5. Basilico C, Moscatelli D. 1992. The FGF family of growth factors and oncogenes. Adv Cancer Res 59: 115-165.
6. Bateman A, Chothia C. 1995. Outline structures for the extracellular domains of the fibroblast growth factor receptors. Nat Struct Biol 2: 1068-1074.
7. Beenken A, Mohammadi M. 2009. The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
8. Beenken A, Mohammadi M. 2011. Craniosynostoses-Mo-lecular genetics, principles of diagnosis, and treatment. Karger, Basel, Switzerland.
9. Beenken A, Mohammadi M. 2012. The structural biology of the FGF19 subfamily. Adv Exp Med Biol 728: 1-24.
10. Beenken A, Eliseenkova AV, Ibrahimi OA, Olsen SK, Mo-hammadi M. 2012. Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1. J Biol Chem 287: 3067-3078.
11. Beer HD, Vindevoghel L, Gait MJ, Revest JM, Duan DR, Mason I, Dickson C, Werner S. 2000. Fibroblast growth factor (FGF) receptor 1-IIIbis anaturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain. J Biol Chem 275: 16091-16097.
12. Bellosta P, Iwahori A, Plotnikov AN, Eliseenkova AV, Ba-silico C, Mohammadi M. 2001. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. Mol Cell Biol 21: 5946-5957.
13. Bergamin E, Hallock PT, Burden SJ, Hubbard SR. 2010. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol Cell 39: 100-109.
14. Blunt AG, Lawshe A, Cunningham ML, Seto ML, Or-nitz DM, MacArthur CA. 1997. Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. J Biol Chem 272: 3733-3738.
15. Chateau MT, Araiz C, Descamps S, Galas S. 2010. Klotho interferes with a novel FGF-signalling pathway and insulin/Igf-like signalling to improve longevity and stress resistance in Caenorhabditis elegans. Aging (Albany NY) 2: 567-581.
16. Chen H, Ma J, Li W, Eliseenkova AV, Xu C, Neubert TA, Miller WT, Mohammadi M. 2007. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 27: 717-730.
17. Chen H, Xu CF, Ma J, Eliseenkova AV, Li W, Pollock PM, Pitteloud N, Miller WT, Neubert TA, Mohammadi M. 2008a. A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc Natl Acad Sci 105: 19660-19665.
18. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H, Boden G. 2008b. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116: 65-68.
19. Colvin JS, White AC, Pratt SJ, Ornitz DM. 2001. Lung hy-poplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development 128: 2095-2106.
20. Delehedde M, Seve M, Sergeant N, Wartelle I, Lyon M, Rudland PS, Fernig DG. 2000. Fibroblast growth factor-2 stimulation of p42/44MAPK phosphorylation and IkB degradation is regulated by heparan sulfate/heparin in rat mammary fibroblasts. J Biol Chem 275: 33905-33910.
21. di Martino E, Tomlinson DC, Knowles MA. 2012. A decade of FGF receptor research in bladder cancer: Past, present, and future challenges. Adv Urol 2012: 429213.
22. Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M, Burgess WH, Jaye M, Schlessinger J. 1990. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J 9: 2685-2692.
23. Dionne CA, Jaye M, Schlessinger J. 1991. Structural diversity and binding of FGF receptors. Ann NY Acad Sci 638: 161-166.
24. Dode C, Levilliers J, Dupont JM, De Paepe A, Le Du N, Soussi-Yanicostas N, Coimbra RS, Delmaghani S, Com-pain-Nouaille S, Baverel F, et al. 2003. Loss-of-function mutations in FGFR1 cause autosomal dominant Kall-mann syndrome. Nat Genet 33: 463-465.
25. Dubrulle J, Pourquie O. 2004. fgf8 mRNA decay establishes a gradient that couples axial elongation topatterningin the vertebrate embryo. Nature 427: 419-422.
26. Eriksson AE, Cousens LS, Weaver LH, Matthews BW. 1991. Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci 88: 3441-3445.
27. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J Clin Invest 108: 169-173.
28. Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149.
29. Faham S, Linhardt RJ, Rees DC. 1998. Diversity does make a difference: Fibroblast growth factor-heparin interactions. Curr Opin Struct Biol 8: 578-586.
30. Falardeau J, Chung WC, Beenken A, Raivio T, Plummer L, Sidis Y, Jacobson-Dickman EE, Eliseenkova AV, Ma J, Dwyer A, et al. 2008. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 118: 2822-2831.
31. Favelyukis S, Till JH, Hubbard SR, Miller WT. 2001. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 8: 1058-1063.
32. Feldman B, Poueymirou W, Papaioannou VE, DeChiara TM, Goldfarb M.1995.RequirementofFGF-4forpostimplan-tation mouse development. Science 267: 246-249.
33. Finch PW, Rubin JS, Miki T, Ron D, Aaronson SA. 1989. Human KGFis FGF-related with properties ofaparacrine effector of epithelial cell growth. Science 245: 752-755.
34. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, et al. 2007. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) Study. JAmSoc Nephrol 18: 2600-2608.
35. Florkiewicz RZ, Sommer A. 1989. Human basic fibroblast growth factor gene encodes four polypeptides: Three initiate translation from non-AUG codons. Proc Natl Acad Sci 86: 3978-3981.
36. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, et al. 2004. Fibroblast growth factor 19 increases metabolic rate and reverses dietaryand leptin-deficient diabetes. Endocrinology 145: 2594-2603.
37. Furdui CM, Lew ED, Schlessinger J, Anderson KS. 2006. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 21: 711-717.
38. Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, et al. 2009. Loss-of-function fibroblast growth factor re-ceptor-2 mutations in melanoma. Mol Cancer Res 7: 41-54.
39. Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M. 2011. Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol 301: F371-F377.
40. Gemel J, Gorry M, Ehrlich GD, MacArthur CA. 1996. Structure and sequence of human FGF8. Genomics 35: 253-257.
41. Givol D, Yayon A. 1992. Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity. FASEB J 6: 3362-3369.
42. Glaser RL, Broman KW, Schulman RL, Eskenazi B, Wyro-bek AJ, Jabs EW. 2003. The paternal-age effect in Apert syndrome is due, in part, to the increased frequency of mutations in sperm. Am J Hum Genet 73: 939-947.
43. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, et al. 2007. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27: 3417-3428.
44. Goetz R, Dover K, Laezza F, Shtraizent N, Huang X, Tchetchik D, Eliseenkova AV, Xu CF, Neubert TA, Ornitz DM, et al. 2009. Crystal structure of a fibroblast growth factor homologous factor (FHF) defines a conserved surface on FHFs for binding and modulation of voltage-gated sodium channels. J Biol Chem 284: 17883-17896.
45. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, Shi M, Eliseenkova AV, Razzaque MS, Moe OW, et al. 2010. Isolated C-terminal tail of FGF23 alleviates hypo-phosphatemiabyinhibitingFGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci 107: 407-412.
46. Goetz R, Ohnishi M, Ding X, Kurosu H, Wang L, Akiyoshi J, Ma J, Gai W, Sidis Y, Pitteloud N, et al. 2012a. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol 32: 1944-1954.
47. Goetz R, Ohnishi M, Kir S, Kurosu H, Wang L, Pastor J, Ma J, Gai W, Kuro OM, Razzaque MS, et al. 2012b. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem 287: 29134-29146.
48. Goldfarb M. 1996. Functions of fibroblast growth factors in vertebrate development. Cytokine Growth Factor Rev 7: 311-325.
49. Hacker U, Nybakken K, Perrimon N. 2005. Heparan sulphate proteoglycans: The sweet side of development. Nat Rev Mol Cell Biol 6: 530-541.
50. Harada M, Murakami H, Okawa A, Okimoto N, Hiraoka S, Nakahara T, Akasaka R, Shiraishi Y, Futatsugi N, Mizu-tani-Koseki Y, et al. 2009. FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and tissue diffusion. Nat Genet 41: 289-298.
51. Harmer NJ, Pellegrini L, Chirgadze D, Fernandez-Recio J, Blundell TL. 2004. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochem 43: 629-640.
52. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, et al. 2003. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17: 1581-1591.
53. Hou J, Kan M, Wang F, Xu JM, Nakahara M, McBride G, McKeehan K, McKeehan WL. 1992. Substitution of putative half-cystine residues in heparin-binding fibroblast growth factor receptors. Loss of binding activity in both two and three loop isoforms. J Biol Chem 267: 17804-17808.
54. Huang Z, Wang H, Lu M, Sun C, Wu X, Tan Y, Ye C, Zhu G, Wang X, Cai L, et al. 2011. A better anti-diabetic recom-binant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE 6: e20669.
55. Hubbard SR. 1997. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572-5581.
56. Hubbard SR. 1999. Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 71: 343-358.
57. Hung KW, Kumar TK, Kathir KM, Xu P, Ni F, Ji HH, Chen MC, Yang CC, Lin FP, Chiu IM, et al. 2005. Solution structure of the ligand binding domain of the fibroblast growth factor receptor: Role of heparin in the activation of the receptor. Biochem 44: 15787-15798.
58. Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM, Mohammadi M. 2001. Structural basis for fibro-blast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci 98: 7182-7187.
59. Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, Mohammadi M. 2004a. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 13: 2313-2324.
60. Ibrahimi OA, Zhang F, Eliseenkova AV, Linhardt RJ, Mo-hammadi M. 2004b. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke cra-niosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet 13: 69-78.
61. Ibrahimi OA, Zhang F, Hrstka SC, Mohammadi M, Lin-hardt RJ. 2004c. Kinetic model for FGF, FGFR, and pro-teoglycan signal transduction complex assembly. Bio-chem 43: 4724-4730.
62. Ibrahimi OA, Chiu ES, McCarthy JG, Mohammadi M.2005. Understanding the molecular basis of Apert syndrome. Plas Reconstr Surg 115: 264-270.
63. Imamura T, Mitsui Y. 1987. Heparan sulfate and heparin as a potentiator or a suppressor of growth of normal and transformed vascular endothelial cells. Exp Cell Res 172: 92-100.
64. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Para-meswara V, Li Y, Goetz R, Mohammadi M, Esser V, et al. 2007. Endocrine regulation of the fasting response by PPARa-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415-425.
65. Inatani M, Irie F, Plump AS, Tessier-Lavigne M, Yama-guchi Y. 2003. Mammalian brain morphogenesis and midline axon guidance require heparan sulfate. Science 302: 1044-1046.
66. Iozzo RV, Zoeller JJ, Nystrom A. 2009. Basement membrane proteoglycans: Modulators par excellence of cancer growth and angiogenesis. Mol Cell 27: 503-513.
67. Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T, Nabeshima YI. 2000. Molecular cloning and expression analyses of mouse b klotho, which encodes a novel Klotho family protein. Mech Dev 98: 115-119.
68. Itoh N, Ornitz DM. 2011. Fibroblast growth factors: From molecular evolution to rolesin development, metabolism and disease. J Biochem 149: 121-130.
69. Johnson DE, Williams LT. 1993. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60: 1-41.
70. Johnson DE, Lee PL, Lu J, Williams LT. 1990. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 10: 4728-4736.
71. Johnson DE, Lu J, Chen H, Werner S, Williams LT. 1991. The human fibroblast growth factor receptor genes: A common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol 11: 4627-4634.
72. Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseen-kova AV, Larochelle WJ, Dhanabal M, Blais S, Ornitz DM, Day LA, et al. 2009. Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Mol Cell Biol 29: 4663-4678.
73. Kalinina J, Dutta K, Ilghari D, Beenken A, Goetz R, Eli-seenkova AV, Cowburn D, Mohammadi M. 2012. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure 20: 77-88.
74. Kato S, Sekine K. 1999. FGF-FGFR signaling in vertebrate organogenesis. Cell Mol Biol (Noisy-le-grand) 45: 631-638.
75. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, Zhang C, Ding L, Micanovic R, Mehrbod SF, Knierman MD, et al. 2008. FGF-21/FGF-21 receptor interaction and activation is determined by b Klotho. J Cell Physiol 215: 1-7.
76. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mange-lsdorf DJ. 2011. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331: 1621-1624.
77. Kiselyov VV, Bock E, Berezin V, Poulsen FM. 2006. NMR structure of the first Ig module of mouse FGFR1. Protein Sci 15: 1512-1515.
78. Kuro-o M. 2012. Klotho and b Klotho. Adv Exp Med Biol 728: 25-40.
79. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et al. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51.
80. Kurosu H, Kuro-o M. 2008. The Klotho gene family and the endocrine fibroblast growth factors. Curr Opin Nephrol Hypertens 17: 368-372.
81. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, et al. 2006. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123.
82. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseen-kova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M. 2007. Tissue-specific expression of b Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282: 26687-26695.
83. Lee PL, Johnson DE, Cousens LS, Fried VA, Williams LT. 1989. Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor. Science 245: 57-60.
84. Lee HC, Tseng WA, Lo FY, Liu TM, Tsai HJ. 2009. FoxD5 mediates anterior-posterior polarity through upstream modulator Fgf signaling during zebra fish somitogenesis. Dev Biol 336: 232-245.
85. Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
86. Lew ED, Bae JH, Rohmann E, Wollnik B, Schlessinger J. 2007. Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. Proc Natl Acad Sci 104: 19802-19807.
87. Lin X, Buff EM, Perrimon N, Michelson AM. 1999. Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. Development 126: 3715-3723.
88. Luo Y, Lu W, Mohamedali KA, Jang JH, Jones RB, Gabriel JL, Kan M, McKeehan WL. 1998. The glycine box: A determinant of specificity for fibroblast growth factor. Bio-chem 37: 16506-16515.
89. Makarenkova HP, Hoffman MP, Beenken A, Eliseenkova AV, Meech R, Tsau C, Patel VN, Lang RA, Mohammadi M. 2009. Differential interactions of FGFs with heparan sul-fate control gradient formation and branching morphogenesis. Sci Signal 2: ra55.
90. Mariani FV, Ahn CP, Martin GR. 2008. Genetic evidence that FGFs have an instructive role in limb proximal-distal patterning. Nature 453: 401-405.
91. Martin GR. 1998. The roles of FGFs in the early development of vertebrate limbs. Genes Dev 12: 1571-1586.
92. Mason IJ, Fuller-Pace F, Smith R, Dickson C. 1994. FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain re-gionalisation and epithelial-mesenchymal interactions. Mech Dev 45: 15-30.
93. Mathieu M, Chatelain E, Ornitz D, Bresnick J, Mason I, Kiefer P, Dickson C. 1995. Receptor binding and mitogenic properties of mouse fibroblast growth factor 3. Modulation of response by heparin. J Biol Chem 270: 24197-24203.
94. McCabe MJ, Gaston-Massuet C, Tziaferi V, Gregory LC, Alatzoglou KS, Signore M, Puelles E, Gerrelli D, Fa-rooqi IS, Raza J, et al. 2011. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. J Clin Endocrinol Metab 96: E1709-E1718.
95. McEwen DG, Ornitz DM. 1997. Determination of fibroblast growth factor expression in mouse, rat and human samples using a single primer pair. Biotechniques 22: 1068-1070.
96. McIntosh I, Bellus GA, Jab EW. 2000. The pleiotropic effects of fibroblast growth factor receptors in mammalian development. Cell Struct Funct 25: 85-96.
97. Metzger RJ, Klein OD, Martin GR, Krasnow MA. 2008. The branching programme of mouse lung development. Nature 453: 745-750.
98. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, Aaronson SA. 1992. Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci 89: 246-250.
99. Mohammadi M, Schlessinger J, Hubbard SR. 1996. Structure of the FGF receptor tyrosine kinase domain reveals a novel auto inhibitory mechanism. Cell 86: 577-587.
100. Mohammadi M, Olsen SK, Goetz R. 2005a. A protein canyon in the FGF-FGF receptor dimer selects from an a la carte menu of heparan sulfate motifs. Curr Opin Struct Biol 15: 506-516.
101. Mohammadi M, Olsen SK, Ibrahimi OA. 2005b. Structural basis for fibroblast growth factor receptor activation. Cy-tokine Growth Factor Rev 16: 107-137.
102. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Nob-litt TW, Otto KA, Reifel-Miller A, Kharitonenkov A. 2007. Molecular determinants ofFGF-21 activity-synergy and cross-talk with PPARg signaling. J Cell Physiol 210: 1-6.
103. Naiche LA, Holder N, Lewandoski M. 2011. FGF4 and FGF8 comprise the wavefront activity that controls somitogen-esis. Proc Natl Acad Sci 108: 4018-4023.
104. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, Mohammadi M, Lanske B, Razzaque MS. 2009. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J 23: 433-441.
105. Naski MC, Wang Q, Xu J, Ornitz DM. 1996. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13: 233-237.
106. Niwa Y, Shimojo H, Isomura A, Gonzalez A, Miyachi H, Kageyama R. 2011. Different types of oscillations in Notch and Fgf signaling regulate the spatiotemporal periodicity of somitogenesis. Genes Dev 25: 1115-1120.
107. Nugent MA, Edelman ER. 1992. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: A mechanism for cooperactivity. Biochem 31: 8876-8883.
108. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, Eliseenkova AV, Mohammadi M, Kuro-o M. 2007. β Klotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci 104: 7432-7437.
109. Olsen SK, Garbi M, Zampieri N, Eliseenkova AV, Ornitz DM, Goldfarb M, Mohammadi M. 2003. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem 278: 34226-34236.
110. Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, Yayon A, Basilico C, Linhardt RJ, Schlessinger J, Moham-madi M. 2004. Insights into the molecular basis for fibroblast growth factor receptor auto inhibition and ligand-binding promiscuity. Proc Natl Acad Sci 101: 935-940.
111. Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, Lao Z, Zhang F, Linhardt RJ, Joyner AL, Mohammadi M. 2006. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev 20: 185-198.
112. Olwin BB, Rapraeger A. 1992. Repression of myogenic differentiation by aFGF, bFGF, and K-FGF is dependent on cellular heparan sulfate. J Cell Biol 118: 631-639.
113. Ornitz DM, ItohN.2001. Fibroblast growth factors. Genome Biol 2: REVIEWS3005.
114. Ornitz DM, Leder P. 1992. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J Biol Chem 267: 16305-16311.
115. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P. 1992. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12: 240-247.
116. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. 1996. Receptor specificity of the fibroblast growth factor family. J Biol Chem 271: 15292-15297.
117. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zim-mer Y, Yayon A, Givol D, Lonai P. 1993. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 158: 475-486.
118. Pautsch A, Zoephel A, Ahorn H, Spevak W, Hauptmann R, Nar H. 2001. Crystal structure of bisphosphorylated IGF-1 receptor kinase: Insight into domain movements upon kinase activation. Structure 9: 955-965.
119. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. 2000. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407: 1029-1034.
120. Pitteloud N, Acierno JS Jr, Meysing A, Eliseenkova AV, Ma J, Ibrahimi OA, Metzger DL, Hayes FJ, Dwyer AA, Hughes VA, et al. 2006a. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonad-ism. Proc Natl Acad Sci 103: 6281-6286.
121. Pitteloud N, Meysing A, Quinton R, Acierno JS, Dwy-er AA, Plummer L, Fliers E, Boepple P, Hayes F, Semi-nara S, et al. 2006b. Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol 254-255: 60-69.
122. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. 1999. Structural basis for FGF receptor dimerization and activation. Cell 98: 641-650.
123. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M. 2000. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101: 413-424.
124. Plotnikov AN, Eliseenkova AV, Ibrahimi OA, Shriver Z, Sasisekharan R, Lemmon MA, Mohammadi M. 2001. Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and auto inhibition. J Biol Chem 276: 4322-4329.
125. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, et al. 2007. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26: 7158-7162.
126. Popovici C, Roubin R, Coulier F, Birnbaum D. 2005. An evolutionary history of the FGF superfamily. Bio Essays 27: 849-857.
127. Powell AK, Fernig DG, Turnbull JE. 2002. Fibroblast growth factor receptors 1 and 2 interact differently with heparin/ heparan sulfate. Implications for dynamic assembly of a ternary signaling complex. J Biol Chem 277: 28554-28563.
128. Prats H, Kaghad M, Prats AC, Klagsbrun M, Lelias JM, Liauzun P, Chalon P, Tauber JP, Amalric F, Smith JA, et al. 1989. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci 86: 1836-1840.
129. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C, et al. 2005. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci 102: 14344-14349.
130. Rapraeger AC, Krufka A, Olwin BB. 1991. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252: 1705-1708.
131. Razzaque MS, Lanske B. 2007. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 194: 1-10.
132. Reinehr T, Woelfle J, Wunsch R, Roth CL. 2012. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: A longitudinal analysis. J Clin Endocrinol Metab 97: 2143-2150.
133. Rodriguez Esteban C, Capdevila J, Economides AN, Pas-cual J, Ortiz A, Izpisua Belmonte JC. 1999. The novel Cer-like protein Caronte mediates the establishment of embryonic left-right asymmetry. Nature 401: 243-251.
134. Roghani M, Moscatelli D. 2007. Prostate cells express two isoforms of fibroblast growth factor receptor 1 with different affinities for fibroblast growth factor-2. Prostate 67: 115-124.
135. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. 2000. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6: 743-750.
136. Sekine K, Ohuchi H, Fujiwara M, Yamasaki M, Yoshizawa T, Sato T, Yagishita N, Matsui D, Koga Y, Itoh N, et al. 1999. Fgf10 is essential for limb and lung formation. Nat Genet 21: 138-141.
137. Seo JH, Suenaga A, Hatakeyama M, Taiji M, Imamoto A. 2009. Structural and functional basis of a role for CRKL in a fibroblast growth factor 8-induced feed-forward loop. Mol Cell Biol 29: 3076-3087.
138. Serls AE, Doherty S, Parvatiyar P, Wells JM, Deutsch GH. 2005. Different thresholds of fibroblast growth factors pattern the ventral foregut into liver and lung. Development 132: 35-47.
139. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci 98: 6500-6505.
140. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. 2002. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143: 3179-3182.
141. Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M. 2001. A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J Biol Chem 276: 11031-11040.
142. Stauber DJ, DiGabriele AD, Hendrickson WA. 2000. Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci 97: 49-54.
143. Sun X, Meyers EN, Lewandoski M, Martin GR. 1999. Targeted disruption of Fgf8 causes failure of cell migration in the gastrulating mouse embryo. Genes Dev 13: 1834-1846.
144. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koya-ma Y, Kimura M, Asada M, Komi-Kuramochi A, Oka S, Imamura T. 2008. β Klotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22: 1006-1014.
145. Tanaka Y, Okada Y, Hirokawa N. 2005. FGF-induced vesicular release of Sonic hedgehog and retinoic acid in leftward nodal flow is critical for left-right determination. Nature 435: 172-177.
146. Tekin M, Hismi BO, Fitoz S, Ozdag H, Cengiz FB, Sirmaci A, Aslan I, Inceoglu B, Yuksel-Konuk EB, Yilmaz ST, et al. 2007. Homozygous mutations in fibroblast growth factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontia. Am J Hum Genet 80: 338-344.
147. Tekin M, Ozturkmen Akay H, Fitoz S, Birnbaum S, Cen-giz FB, Sennaroglu L, Incesulu A, Yuksel Konuk EB, Ha-sanefendioglu Bayrak A, Senturk S, et al. 2008. Homozy-gous FGF3 mutations result in congenital deafness with inner ear agenesis, microtia, and microdontia. Clin Genet 73: 554-565.
148. Trarbach EB, Abreu AP, Silveira LF, Garmes HM, Bap-tista MT, Teles MG, Costa EM, Mohammadi M, Pitteloud N, Mendonca BB, et al. 2010. Nonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiency. J Clin Endocrinol Metab 95: 3491-3496.
149. Trueb B.2011. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell Mol Life Sci 68: 951-964.
150. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. 2006. Klo-tho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774.
151. Vega-Hernandez M, Kovacs A, De Langhe S, Ornitz DM. 2011. FGF10/FGFR2b signaling is essential for cardiac fibroblast development and growth of the myocardium. Development 138: 3331-3340.
152. Wahl MB, Deng C, Lewandoski M, Pourquie O. 2007. FGF signaling acts upstream of the NOTCH and WNT signaling pathways to control segmentation clock oscillations in mouse somitogenesis. Development 134: 4033-4041.
153. Wang F, Kan M, Yan G, Xu J, McKeehan WL. 1995. Alternately spliced NH2-terminal immunoglobulin-like Loop I in the ecto domain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1. J Biol Chem 270: 10231-10235.
154. Wang C, Chung BC, Yan H, Lee SY, Pitt GS. 2012. Crystal structure of the ternary complex of a NaV C-terminal domain, a fibroblast growth factor homologous factor, and calmodulin. Structure 20: 1167-1176.
155. White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM. 2000. Autosomal dominant hypophospha-taemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348.
156. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. 2001. Autosomal-dominant hypo-phosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 2079-2086.
157. Wilkie AO. 2005. Bad bones, absent smell, selfish testes: The pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16: 187-203.
158. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P, et al. 1995. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9: 165-172.
159. Wilkie AO, Patey SJ, Kan SH, van den Ouweland AM, Ha-mel BC. 2002. FGFs, their receptors, and human limb malformations: clinical and molecular correlations. Am J Med Genet 112: 266-278.
160. Wu X, Ge H, Gupte J, Weiszmann J, Shimamoto G, Stevens J, Hawkins N, Lemon B, Shen W, Xu J, et al. 2007. Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem 282: 29069-29072.
161. Wu X, Lemon B, Li X, Gupte J, Weiszmann J, Stevens J, Hawkins N, Shen W, Lindberg R, Chen JL, et al. 2008. C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem 283: 33304-33309.
162. Wuechner C, Nordqvist AC, Winterpacht A, Zabel B, Schalling M. 1996. Developmental expression of splicing variants of fibroblast growth factor receptor 3 (FGFR3) in mouse. Int J Dev Biol 40: 1185-1188.
163. Xu J, Nakahara M, Crabb JW, Shi E, Matuo Y, Fraser M, Kan M, Hou J, McKeehan WL. 1992. Expression and immunochemical analysis of rat and human fibroblast growth factor receptor (flg) isoforms. J Biol Chem 267: 17792-17803.
164. Xu J, Lawshe A, MacArthur CA, Ornitz DM. 1999. Genomic structure, mapping, activity and expression of fibroblast growth factor 17. Mech Dev 83: 165-178.
165. Xu R, Ori A, Rudd TR, Uniewicz KA, Ahmed YA, Gui-mond SE, Skidmore MA, Siligardi G, Yates EA, Fernig DG. 2012. Diversification of the structural determinants of fibroblast growth factor-heparin interactions: Implications for binding specificity. J Biol Chem.
166. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841-848.
167. Yayon A, Zimmer Y, Shen GH, Avivi A, Yarden Y, Givol D. 1992.Aconfined variable region confers ligand specificity on fibroblast growth factor receptors: Implications for the origin of the immunoglobulin fold. EMBO J 11: 1885-1890.
168. Ye S, Luo Y, Lu W, Jones RB, Linhardt RJ, Capila I, Toida T, Kan M, Pelletier H, McKeehan WL. 2001. Structural basis for interactionofFGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Biochem 40: 14429-14439.
169. Yeh BK, Igarashi M, Eliseenkova AV, Plotnikov AN, Sher I, Ron D, Aaronson SA, Mohammadi M. 2003. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl AcadSci 100: 2266-2271.
170. Yie J, Wang W, Deng L, Tam LT, Stevens J, Chen MM, Li Y, Xu J, Lindberg R, Hecht R, et al. 2012. Understanding the physical interactions in the FGF21/FGFR/b-Klotho complex: Structural requirements and implications in FGF21 signaling. Chem Biol Drug Des 79: 398-410.
171. Yoon SR, Qin J, Glaser RL, Jabs EW, Wexler NS, Sokol R, Arnheim N, Calabrese P.2009. The ups and downs of mutation frequencies during aging can account for the Apert syndrome paternal age effect. PLoS Genet 5: e1000558.
172. Yu K, Ornitz DM. 2001. Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes. Proc Natl Acad Sci 98: 3641-3643.
173. Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeehan WL. 2000a. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 275: 15482-15489.
174. Yu K, Herr AB, Waksman G, Ornitz DM. 2000b. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci 97: 14536-14541.
175. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, White KE. 2005. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146: 4647-4656.
176. Zhang JD, Cousens LS, Barr PJ, Sprang SR. 1991. Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1b. Proc Natl Acad Sci 88: 3446-3450.
177. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Moha-mmadi M, Ornitz DM. 2006. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281: 15694-15700.
178. Zhang F, Zhang Z, Lin X, Beenken A, Eliseenkova AV, Mohammadi M, Linhardt RJ. 2009. Compositional analysis on heparin/heparan sulfate interacting with FGF†FGFR complexes. Biochemistry 48: 8379-8386.
179. Zhu X, Komiya H, Chirino A, Faham S, Fox GM, Arakawa T, Hsu BT, Rees DC. 1991. Three-dimensional structures of acidic and basic fibroblast growth factors. Science 251: 90-93.